Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation

References

• Boon T, Van den Eynde B. Tumour immunology. Curr Opin Immunol 2003; 15:129–30.
   PubMedGoogle Scholar
• Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:372–83.
   PubMed Web of Science ®Google Scholar
• Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, . Advances in specific immunotherapy for prostate cancer. Eur Urol 2008; 53:694–708.
   PubMedGoogle Scholar
• Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, . Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2007; 56:429–45.
   PubMed Web of Science ®Google Scholar
• Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53:227–30.
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, . Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9:6357–62.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91:528–39.
   PubMed Web of Science ®Google Scholar
• Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, . Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007; 38:696–701.
   PubMed Web of Science ®Google Scholar
• Barwe SP, Maul RS, Christiansen JJ, Anilkumar G, Cooper CR, Kohn DB, . Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol 2007; 30:899–904.
   PubMed Web of Science ®Google Scholar
• Yao V, Parwani A, Maier C, Heston WD, Bacich DJ. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 2008; 68:9070–7.
   PubMed Web of Science ®Google Scholar
• Rajasekaran SA, Christiansen JJ, Schmid I, Oshima E, Ryazantsev S, Sakamoto K, . Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther 2008; 7:2142–51.
   PubMedGoogle Scholar
• Wang K, Gao X, Pang J, Liu X, Cai Y, Zhang Y, . Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol 2009; 27:26–32.
   PubMed Web of Science ®Google Scholar
• Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59:3192–8.
   PubMed Web of Science ®Google Scholar
• Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007; 70:385–90.
   PubMed Web of Science ®Google Scholar
• Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains. J Immunol 1994; 152:163–75.
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213–9.
   PubMed Web of Science ®Google Scholar
• Peters B, Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 31:6–132.
   Google Scholar
• Murphy GP, Tjoa BA, Simmons SJ, Rogers MK, Kenny GM, Jarisch J. Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 2000; 43:59–62.
   PubMed Web of Science ®Google Scholar
• Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, . Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006; 66:811–21.
   PubMed Web of Science ®Google Scholar
• Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Böhme C, Schmid HP, . Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006; 55:1524–33.
   PubMed Web of Science ®Google Scholar
• Knight D, Peterson AC, Rini BI, Harlin H, Gajewski TF, Stadler WM. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate 2009; 69:142–8.
   PubMed Web of Science ®Google Scholar
• Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62:5807–12.
   PubMed Web of Science ®Google Scholar
• Mincheff M, Zoubak S, Altankova I, Tchakarov S, Makogonenko Y, Botev C, . Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther 2003; 10:907–17.
   PubMed Web of Science ®Google Scholar
• Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T B lymphoblast hybrids. Immunogenetics 1985; 21:235–46.
   PubMed Web of Science ®Google Scholar
• Lozzio BB, Lozzio CB. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer 1977; 19:136–9.
   PubMedGoogle Scholar
• Brusa D, Garetto S, Chiorino G, Scatolini M, Migliore E, Camussi G, . Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 2008; 26:6422–32.
   PubMed Web of Science ®Google Scholar
• Russo C, Ng AK, Pellegrino MA, Ferrone S. The monoclonal antibody CR11–351 discriminates HLA-A2 variants identified by T cells. Immunogenetics 1983; 18:23–35.
   PubMed Web of Science ®Google Scholar
• Burlingham WJ, Jankowska-Gan E, DeVito-Haynes L, Fechner JH Jr, Hogan KT, Claas FH, . HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. J Immunol 1998; 161:6705–14.
   PubMedGoogle Scholar
• Manders EEM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal images. J Microscopy 1993; 169:375–82.
   PubMed Web of Science ®Google Scholar
• Piston DW, Kremers GJ. Fluorescent protein FRET: the good, the bad and the ugly. Trends Biochem Sci 2007; 32:407–14.
   PubMed Web of Science ®Google Scholar
• Shyu YJ, Suarez CD, Hu CD. Visualization of ternary complexes in living cells by using a BiFC-based FRET assay. Nat Protoc 2008; 3:1693–702.
   PubMed Web of Science ®Google Scholar
• Prechtel AT, Steinkasserer A. CD83: an update on functions and prospects of the maturation marker of dendritic cells. Arch Dermatol Res 2007; 299:59–69.
   PubMed Web of Science ®Google Scholar
• Förster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol 2008; 8:362–71.
   PubMed Web of Science ®Google Scholar
• Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther 2007; 6:1932–7.
   PubMed Web of Science ®Google Scholar